GSK Q3 Core Earnings Edge Lower, Sales Increase; 2026 Outlook Affirmed

04:48 AM EDT, 10/28/2026 (MT Newswires) -- GSK (GSK) on Wednesday reported Q3 core earnings of 0.546 British pounds ($0.73) per share, down from 0.55 British pounds a year ago. Analysts polled by Factset expected 0.589 British pounds. The pharmaceutical company said revenue for the quarter ended Sept. 30 was 8.89 billion pounds, up from 8.55 billion pounds a year earlier. Analysts surveyed by FactSet expected 8.83 billion pounds. GSK reaffirmed its full-year 2026 guidance, expecting revenue growth of 3% to 5%, and core EPS growth of 7% to 9%, the company said.